BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21290407)

  • 1. γ-Aminobutyric acid type B receptor changes in the rat striatum and substantia nigra following intrastriatal quinolinic acid lesions.
    Rekik L; Daguin-Nerrière V; Petit JY; Brachet P
    J Neurosci Res; 2011 Apr; 89(4):524-35. PubMed ID: 21290407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical and anatomical changes in the striatum and substantia nigra following quinolinic acid lesions in the striatum of the rat: a detailed time course of the cellular and GABA(A) receptor changes.
    Brickell KL; Nicholson LF; Waldvogel HJ; Faull RL
    J Chem Neuroanat; 1999 Oct; 17(2):75-97. PubMed ID: 10585160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GABA and GABAA receptor changes in the substantia nigra of the rat following quinolinic acid lesions in the striatum closely resemble Huntington's disease.
    Nicholson LF; Faull RL; Waldvogel HJ; Dragunow M
    Neuroscience; 1995 Jun; 66(3):507-21. PubMed ID: 7644016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease.
    Tattersfield AS; Croon RJ; Liu YW; Kells AP; Faull RL; Connor B
    Neuroscience; 2004; 127(2):319-32. PubMed ID: 15262322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential role of GABAA and GABAB receptors in two distinct output stations of the rat striatum: studies on the substantia nigra pars reticulata and the globus pallidus.
    Ikeda H; Kotani A; Koshikawa N; Cools AR
    Neuroscience; 2010 Apr; 167(1):31-9. PubMed ID: 20132872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease.
    Senatorov VV; Ren M; Kanai H; Wei H; Chuang DM
    Mol Psychiatry; 2004 Apr; 9(4):371-85. PubMed ID: 14702090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
    Harris CA; Miranda AF; Tanguay JJ; Boegman RJ; Beninger RJ; Jhamandas K
    Br J Pharmacol; 1998 May; 124(2):391-9. PubMed ID: 9641558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time- and dose-dependent 45Ca2+ accumulation in rat striatum and substantia nigra after an intrastriatal injection of quinolinic acid.
    Gramsbergen JB; van der Sluijs-Gelling AJ
    Exp Neurol; 1993 Jun; 121(2):261-9. PubMed ID: 8339777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease.
    Allen KL; Waldvogel HJ; Glass M; Faull RL
    J Chem Neuroanat; 2009 Jul; 37(4):266-81. PubMed ID: 19481011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
    Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
    Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration.
    Ghorayeb I; Puschban Z; Fernagut PO; Scherfler C; Rouland R; Wenning GK; Tison F
    Exp Neurol; 2001 Jan; 167(1):133-47. PubMed ID: 11161601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of immunoreactivity for glial fibrillary acidic protein (GFAP) in astrocytes as a marker for profound tissue damage in substantia nigra and basal cortical areas after status epilepticus induced by pilocarpine in rat.
    Schmidt-Kastner R; Ingvar M
    Glia; 1994 Nov; 12(3):165-72. PubMed ID: 7851985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CGP 56999A, a GABA(B) receptor antagonist, enhances expression of brain-derived neurotrophic factor and attenuates dopamine depletion in the rat corpus striatum following a 6-hydroxydopamine lesion of the nigrostriatal pathway.
    Enna SJ; Reisman SA; Stanford JA
    Neurosci Lett; 2006 Oct; 406(1-2):102-6. PubMed ID: 16890350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subpopulations of neurons in rat substantia nigra display GABA(B)R2 receptor immunoreactivity.
    Ng TK; Yung KK
    Brain Res; 2001 Nov; 920(1-2):210-6. PubMed ID: 11716827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adrenalectomy counteracts the local modulation of astroglial fibroblast growth factor system without interfering with the pattern of 6-OHDA-induced dopamine degeneration in regions of the ventral midbrain.
    Chadi G; Silva C; Maximino JR; Fuxe K; da Silva GO
    Brain Res; 2008 Jan; 1190():23-38. PubMed ID: 18086466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral and anatomical effects of quinolinic acid in the striatum of the hemiparkinsonian rat.
    Olds ME; Jacques DB; Kopyov O
    Synapse; 2005 Jan; 55(1):26-36. PubMed ID: 15499610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions of dopaminergic and GABAergic neurotransmission: impact of 6-hydroxydopamine lesions into the substantia nigra of rats.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1995 Oct; 275(1):237-44. PubMed ID: 7562556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
    Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
    J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The subcellular localization of GABA(B) receptor subunits in the rat substantia nigra.
    Boyes J; Bolam JP
    Eur J Neurosci; 2003 Dec; 18(12):3279-93. PubMed ID: 14686901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Divergent regulatory mechanisms governing BDNF mRNA expression in cerebral cortex and substantia nigra in response to striatal target ablation.
    Rite I; Machado A; Cano J; Venero JL
    Exp Neurol; 2005 Mar; 192(1):142-55. PubMed ID: 15698628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.